Toronto, Ontario – Cyclica Inc., a biotechnology company offering a novel computational proteome-wide screening approach for drug discovery, has been recognized by PM360 with a “2016 Innovator Award”. Whether hypothetical, pre-clinical, clinical, or FDA-approved, Cyclica’s Ligand Express™ platform offers proteome-wide insight into a small molecule’s effect within the human body by predicting drug-protein interactions. This information can augment drug discovery pipelines and efficiently translate novel medicines from the drawing board to bench, and potentially to the clinic. This platform is currently being utilized by several third-parties to develop safer and more effective therapeutics, and PM360 has recognized Cyclica’s ongoing contributions to the drug development ecosystem in North America.
Naheed Kurji, President and CEO of Cyclica, was enthusiastic upon hearing the news: “We are thrilled to have been selected as one of this year’s recipients of PM360’s 2016 Innovator Award. Our clients are looking for a faster and cheaper way to bring safer and more effective drugs to the market, and our continued goal is to support the biotech industry in the North American and global markets to address their needs. We greatly appreciate the recognition that PM360 has provided for our efforts in this pursuit. Going forward, we are focused on commercialization and scale, as well as on continued innovation. We currently have many ‘irons in the fire’, and with the continued support of biotech leaders such as PM360, we plan to accelerate our growth and implement our technology as a utility platform in the R&D value chain globally.”
Cyclica Inc. has developed, validated, and patented a structure-based proteome-wide screening platform, Ligand Express™, that currently features PROBEx (proteome-screening), SWITCHx (ligand effect prediction) and DIVEx (systems biology & drug-protein interactomes). Ligand Express™ is unique in that it is a drug-centric platform. For a small molecule ligand, Ligand Express™ automatically generates an intelligent list of ligand-protein interactions by searching through a large proprietary database of all available structurally characterized proteins. The platform provides a panoramic view of a small molecule ligand to better understand on- and off-target interactions, and is valuable in finding novel desirable or undesirable targets. By gaining insights into a ligand’s polypharmacology, Cyclica’s clients can identify unknown targets, prioritize lead candidates, elucidate adverse effects, and understand repurposing opportunities.
PM360 is the premier, must-read magazine for marketing decision makers in the pharmaceutical, biotech, and medical device industries. Published monthly, PM360 is the only journal that focuses on delivering the full spectrum of practical information necessary for product managers and pharma marketing professionals to succeed in the complex and highly regulated healthcare environment. The journal’s targeted and insightful editorial focuses on issues that directly impact critical decision making, including: planning and implementation of cutting edge strategies, trends, the latest technological advances, branding/marketing, advertising/promotion, patient/professional education, sales, market research, PR, and leadership. Additionally, the “360” in our title signifies the combination of this critical, how-to info with personal and career insights for an enjoyable and thought-provoking read. By providing the full circle of enriching content, PM360 is truly an indispensable tool for busy and productive marketing professionals to stay at the top of their game.